TW202321228A - 苯並二噁烷類化合物、其製備方法與應用 - Google Patents

苯並二噁烷類化合物、其製備方法與應用 Download PDF

Info

Publication number
TW202321228A
TW202321228A TW111129587A TW111129587A TW202321228A TW 202321228 A TW202321228 A TW 202321228A TW 111129587 A TW111129587 A TW 111129587A TW 111129587 A TW111129587 A TW 111129587A TW 202321228 A TW202321228 A TW 202321228A
Authority
TW
Taiwan
Prior art keywords
piperidinyl
piperazinyl
methyl
hydrogen
formyl
Prior art date
Application number
TW111129587A
Other languages
English (en)
Chinese (zh)
Inventor
鄧賢明
黃偉
吳振華
云彩紅
建明 張
黃鑫
Original Assignee
大陸商南京紅云生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商南京紅云生物科技有限公司 filed Critical 大陸商南京紅云生物科技有限公司
Publication of TW202321228A publication Critical patent/TW202321228A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111129587A 2021-08-06 2022-08-05 苯並二噁烷類化合物、其製備方法與應用 TW202321228A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110901100.1 2021-08-06
CN202110901100 2021-08-06
CN202210917076.5 2022-08-01
CN202210917076 2022-08-01

Publications (1)

Publication Number Publication Date
TW202321228A true TW202321228A (zh) 2023-06-01

Family

ID=85155315

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129587A TW202321228A (zh) 2021-08-06 2022-08-05 苯並二噁烷類化合物、其製備方法與應用

Country Status (3)

Country Link
CN (1) CN117794923A (fr)
TW (1) TW202321228A (fr)
WO (1) WO2023011610A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2009112490A1 (fr) * 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides en tant qu'inhibiteurs de zap-70
CN110944989B (zh) * 2017-07-19 2021-06-25 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物
WO2020253860A1 (fr) * 2019-06-21 2020-12-24 江苏豪森药业集团有限公司 Inhibiteur de dérivé d'oxyde de phosphore aryle, son procédé de préparation et son utilisation
WO2021018003A1 (fr) * 2019-07-26 2021-02-04 贝达药业股份有限公司 Inhibiteur d'egfr, composition et procédé de préparation correspondant
WO2021104305A1 (fr) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 Inhibiteur d'un dérivé polycyclique contenant de l'azote, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
WO2023011610A1 (fr) 2023-02-09
CN117794923A (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
EP3672949B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
CN105934246B (zh) 作为bet溴域抑制剂的四氢喹啉组成物
CN106661039B (zh) 酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
US8962642B2 (en) 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
US7935706B2 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP2766360B1 (fr) Activateurs de guanylate cyclase soluble
US20040235886A1 (en) Gyrase inhibitors and uses thereof
NZ753651A (en) (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides
WO2021088945A1 (fr) Composé utilisé comme inhibiteur de shp2 et son utilisation
WO2022135432A1 (fr) Composés hétérocycliques macrocycliques utilisés en tant qu'inhibiteurs d'egfr et leur utilisation
JP2011527667A (ja) ハロ置換ピリミドジアゼピン
TW201728592A (zh) Ｉｒａｋ抑制劑及其用途
TW201217386A (en) Heterocyclic compound and use thereof
US11440907B1 (en) Antiproliferation compounds and uses thereof
WO2021238827A1 (fr) Inhibiteur d'egfr, son procédé de préparation et son utilisation
CN110234637A (zh) 用作irak抑制剂的吡唑酰胺化合物
EP3378491A1 (fr) Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash)
TW202321228A (zh) 苯並二噁烷類化合物、其製備方法與應用
WO2021249324A1 (fr) Composé d'alcényle pyrimidine, procédé de préparation associé et son application
RU2811969C2 (ru) Антипролиферативные соединения и их применения
RU2795850C2 (ru) Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
TW202317560A (zh) Ｃｄｋ２抑制劑及其使用方法
TW202334141A (zh) 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法